DK0441955T3 - Fremstilling af biologisk aktiv insulinlignende vækstfaktor I ud fra højekspressionsværtscellesystemer - Google Patents

Fremstilling af biologisk aktiv insulinlignende vækstfaktor I ud fra højekspressionsværtscellesystemer

Info

Publication number
DK0441955T3
DK0441955T3 DK90914315.8T DK90914315T DK0441955T3 DK 0441955 T3 DK0441955 T3 DK 0441955T3 DK 90914315 T DK90914315 T DK 90914315T DK 0441955 T3 DK0441955 T3 DK 0441955T3
Authority
DK
Denmark
Prior art keywords
igf
preparation
host cell
growth factor
biologically active
Prior art date
Application number
DK90914315.8T
Other languages
Danish (da)
English (en)
Inventor
James A Miller
Philip K Hsieh
Larry B Tsai
Original Assignee
Amgen Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Amgen Inc filed Critical Amgen Inc
Application granted granted Critical
Publication of DK0441955T3 publication Critical patent/DK0441955T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/65—Insulin-like growth factors, i.e. somatomedins, e.g. IGF-1, IGF-2
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/62—DNA sequences coding for fusion proteins
    • C12N15/625—DNA sequences coding for fusion proteins containing a sequence coding for a signal sequence
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
    • C07K2319/74—Fusion polypeptide containing domain for protein-protein interaction containing a fusion for binding to a cell surface receptor
    • C07K2319/75—Fusion polypeptide containing domain for protein-protein interaction containing a fusion for binding to a cell surface receptor containing a fusion for activation of a cell surface receptor, e.g. thrombopoeitin, NPY and other peptide hormones

Landscapes

  • Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
DK90914315.8T 1989-08-25 1990-08-21 Fremstilling af biologisk aktiv insulinlignende vækstfaktor I ud fra højekspressionsværtscellesystemer DK0441955T3 (da)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US07/398,699 US5158875A (en) 1989-08-25 1989-08-25 Production of biologically active insulin-like growth factor i from high expression host cell systems

Publications (1)

Publication Number Publication Date
DK0441955T3 true DK0441955T3 (da) 1996-10-07

Family

ID=23576440

Family Applications (1)

Application Number Title Priority Date Filing Date
DK90914315.8T DK0441955T3 (da) 1989-08-25 1990-08-21 Fremstilling af biologisk aktiv insulinlignende vækstfaktor I ud fra højekspressionsværtscellesystemer

Country Status (10)

Country Link
US (1) US5158875A (de)
EP (1) EP0441955B1 (de)
JP (1) JPH04501514A (de)
AT (1) ATE140029T1 (de)
AU (1) AU644105B2 (de)
CA (1) CA2023969A1 (de)
DE (1) DE69027666T2 (de)
DK (1) DK0441955T3 (de)
ES (1) ES2089029T3 (de)
WO (1) WO1991002807A1 (de)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5316932A (en) * 1989-03-24 1994-05-31 Duke University Homogeneous denatured human 06-guanine alkyltransferase prepared by immunoaffinity chromatography using monoclonal antibody specific for enzyme
EP0545999B1 (de) * 1990-08-20 1997-06-04 Novo Nordisk A/S Prozess für die Herstellung von biologisch aktivem IGF-1 durch Verwendung von amino-terminal verlängertem IGF-1
US5646016A (en) * 1991-02-06 1997-07-08 Genetics Institute, Inc. Peptide and protein fusions to thioredoxin, thioredoxin-like molecules, and modified thioredoxin-like molecules
US5378613A (en) * 1991-09-24 1995-01-03 Eli Lilly And Company Method for increased expression of low molecular weight recombinant polypeptides
US5288931A (en) * 1991-12-06 1994-02-22 Genentech, Inc. Method for refolding insoluble, misfolded insulin-like growth factor-I into an active conformation
US5958764A (en) * 1992-04-30 1999-09-28 Baylor College Of Medicine Specific expression vectors and methods of use
WO1994023042A1 (en) * 1993-03-29 1994-10-13 E.I. Du Pont De Nemours And Company A method for enhancing the production of biologically active recombinant proteins
US5663304A (en) * 1993-08-20 1997-09-02 Genentech, Inc. Refolding of misfolded insulin-like growth factor-I
US5407810A (en) * 1993-08-20 1995-04-18 Genentech, Inc. Aqueous multiple-phase isolation of polypeptide
SE9303784D0 (sv) * 1993-11-16 1993-11-16 Kabi Pharmacia Ab Igf
US5451660A (en) * 1993-12-13 1995-09-19 Genentech, Inc. Method for purifying polypeptides
WO1995016708A1 (en) * 1993-12-17 1995-06-22 Novo Nordisk A/S Proinsulin-like compounds
WO1996007744A1 (en) * 1994-09-08 1996-03-14 Chiron Corporation A method of improved production of insulin-like growth factor
US5712249A (en) * 1994-09-08 1998-01-27 Ciba-Geigy Corporation Use of insulin-like growth factors I and II for inhibition of inflammatory response
US5789547A (en) * 1995-06-07 1998-08-04 Celtrix Pharmaceuticals, Inc. Method of producing insulin-like growth factor-I (IGF-I) and insulin-like growth factor binding protein-3 (IGFBP-3) with correct folding and disulfide bonding
SG121902A1 (en) * 2000-01-11 2006-05-26 Maxygen Inc Integrated systems for diversity generation and screening
US20080119433A1 (en) * 2006-07-06 2008-05-22 Aaron Thomas Tabor Compositions and Methods for Genetic Modification of Cells Having Cosmetic Function to Enhance Cosmetic Appearance
CL2007002502A1 (es) * 2006-08-31 2008-05-30 Hoffmann La Roche Variantes del factor de crecimiento similar a insulina-1 humano (igf-1) pegilados en lisina; metodo de produccion; proteina de fusion que la comprende; y su uso para tratar la enfermedad de alzheimer.
EP2059530B1 (de) * 2006-08-31 2012-08-29 F.Hoffmann-La Roche Ag Verfahren zur herstellung des insulinähnlichen wachstumsfaktors-i
WO2009121759A2 (en) * 2008-04-03 2009-10-08 F. Hoffmann-La Roche Ag Use of pegylated igf-i variants for the treatment of neuromuscular disorders
CN101965516A (zh) * 2008-04-03 2011-02-02 弗·哈夫曼-拉罗切有限公司 聚乙二醇化胰岛素样生长因子测定
BR112012000865A2 (pt) 2009-07-17 2019-09-24 T Tabor Aaron "composição e método para a modificação genética cosmética de células substancialmente intactas"
US20110152188A1 (en) * 2009-12-23 2011-06-23 Hanns-Christian Mahler Pharmaceutical compositions of igf/i proteins
US9675671B2 (en) * 2014-01-12 2017-06-13 Igf Oncology, Llc Fusion proteins containing insulin-like growth factor-1 and epidermal growth factor and variants thereof and uses thereof
CN112892220B (zh) * 2021-01-19 2023-02-17 南开大学 一种高效的活性蛋白分离方法与装置
CN114292800B (zh) * 2021-12-27 2024-08-20 武汉佰乐博生物技术有限公司 用于igf-1基因重组表达的重组细胞和重组表达方法

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4532207A (en) * 1982-03-19 1985-07-30 G. D. Searle & Co. Process for the preparation of polypeptides utilizing a charged amino acid polymer and exopeptidase
FR2594846B1 (fr) * 1986-02-21 1989-10-20 Genetica Procede de preparation de la serum albumine humaine mature
EP0371041A1 (de) * 1987-06-24 1990-06-06 Novo Nordisk A/S Verfahren für die herstellung eines proteins oder polypeptides, dns-sequenz, die dieses polypeptid kodiert, mikroorganismus, der diese dns-sequenz beinhaltet, sowie das polypeptid und seine verwendung als pharmazeutisches präparat

Also Published As

Publication number Publication date
CA2023969A1 (en) 1991-02-26
JPH04501514A (ja) 1992-03-19
DE69027666T2 (de) 1996-11-07
EP0441955A4 (en) 1992-07-15
AU644105B2 (en) 1993-12-02
US5158875A (en) 1992-10-27
ES2089029T3 (es) 1996-10-01
DE69027666D1 (de) 1996-08-08
WO1991002807A1 (en) 1991-03-07
EP0441955A1 (de) 1991-08-21
EP0441955B1 (de) 1996-07-03
ATE140029T1 (de) 1996-07-15
AU6425490A (en) 1991-04-03

Similar Documents

Publication Publication Date Title
DK0441955T3 (da) Fremstilling af biologisk aktiv insulinlignende vækstfaktor I ud fra højekspressionsværtscellesystemer
VAN WYK et al. Evidence from radioligand assays that somatomedin-C and insulin-like growth factor-I are similar to each other and different from other somatomedins
SE465222C5 (sv) Ett rekombinant, humant faktor VIII-derivat och förfarande för dess framställning
DE3750197D1 (de) Antagonisten des Fibroblasten-Wachstumsfaktors.
EP0722461A4 (de) Expression eines fusionspolypeptides, das ohne leadersequenz aus dem cytoplasma transportiert wird
ATE264872T1 (de) Mit rekombinantem insulin-ähnlichen wachstumsfaktor igf-i vergleichbare rückfaltung von polypeptiden
ATE123949T1 (de) B-ketten-analoge des von blutplättchen abstammenden wachstumsfaktors und verfahren zu deren homogener herstellung.
DK0542863T3 (da) Ekspression af rekombinante polypeptider med forbedret oprensning
ES2147558T3 (es) Nuevos polipeptidos para promover la fijacion celular.
DE69132275D1 (de) Beta-type ähnlicher transformierender wachstumfaktor
WO2002055717A3 (en) Enhanced secretion of a polypeptide by a microorganism
ES2104635T3 (es) Nuevo peptido porcino con una actividad fisiologica (cnp-53).
DK0775750T3 (da) Fremstilling af proteiner ud fra pro-proteiner med fusionsproteiner afledt af furin eller furinanaloge
ATE297461T1 (de) Reguliertes autokrines wachstum von säugerzellen
PT99313A (pt) Processo para a preparacao de proteinas, de viros recombinantes e de vectores de transferencia uteis para a expressao dessas proteinas
DE69126487D1 (de) cDNA für Ratten C-Typ natriuretisches Peptid und Vorläuferprotein
ATE108458T1 (de) Immunglobulin-e-kompetitor.
ES2091237T3 (es) Nuevo procedimiento para la produccion de proteina no fusionada en e. coli.
EA200101161A1 (ru) Способ получения рекомбинантного инсулина из новых гибридных белков
US7589063B2 (en) Molecules which promote hematopoiesis
DK0467839T3 (da) In-vitro-behandling af fusionsproteiner
KR880701073A (ko) 제조합 dna 기법에 의해 생성된 민악티빈
EA200001252A1 (ru) КОМПОЗИЦИЯ РЕКОМБИНАНТНОГО ИНТЕРФЕРОНА-β-1A(IFN-β-1A) ЧЕЛОВЕКА
Stepanik et al. Primary structure of human alpha 2-macroglobulin. III. Primary structure of three large disulfide-bridged CNBr fragments, located in the COOH-terminal part of alpha 2-macroglobulin and accounting for 301 residues.
EA200000709A1 (ru) Бета-липотропин и его применения